Loading…
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $19M | $-47M | $-65M | $-37M | -24.3% | -29.3% | - |
| 2024 | $26M | $-51M | $-62M | $-42M | -21.6% | -22.8% | - |
| 2023 | $34M | $-50M | $-51M | $1M | -16.1% | -42.2% | - |
| 2022 | $59M | $-8M | $-22M | $-21M | -6.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 59.08 | 34.16 | 26.39 | 18.67 |
| Cost Of Revenue | 0 | 0 | 0 | 0.30 |
| Gross Profit | 0 | 0 | 26.39 | 18.36 |
| Operating Expense | 85.72 | 103.58 | 100.89 | 87.33 |
| Operating Income | -26.65 | -69.42 | -74.50 | -68.97 |
| EBITDA | -8.40 | -49.92 | -50.92 | -47.22 |
| EBIT | -26.65 | -69.42 | -74.50 | -68.97 |
| Pretax Income | -26.06 | -64.36 | -71.41 | -66.29 |
| Tax Provision | -3.73 | -13.74 | -9.38 | -1.51 |
| Net Income | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Common Stockholders | -22.33 | -50.62 | -62.03 | -64.78 |
| Total Expenses | 85.72 | 103.58 | 100.89 | 87.64 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 0.59 | 5.05 | 3.11 | 2.66 |
| Research And Development | 48.36 | 56.52 | 55.11 | 47.75 |
| Selling General And Administration | 24.90 | 33.31 | 30.74 | 29.21 |
| Normalized EBITDA | -8.40 | -49.92 | -50.92 | -47.22 |
| Normalized Income | -22.33 | -50.62 | -62.03 | -64.78 |
| Basic EPS | -0.26 | -0.51 | -0.61 | -0.57 |
| Diluted EPS | -0.26 | -0.51 | -0.61 | -0.57 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.14 | 0.21 | 0.13 | 0.02 |
| Net Income From Continuing Operation Net Minority Interest | -22.33 | -50.62 | -62.03 | -64.78 |
| Reconciled Depreciation | 18.25 | 19.50 | 23.58 | 21.75 |
| Reconciled Cost Of Revenue | 0 | 0 | 0 | 0.30 |
| Net Interest Income | 0.59 | 5.05 | 3.11 | 2.66 |
| Net Income From Continuing And Discontinued Operation | -22.33 | -50.62 | -62.03 | -64.78 |
| Total Operating Income As Reported | -26.65 | -69.42 | -74.50 | -68.97 |
| Diluted Average Shares | 85.32 | 99.68 | 102.36 | 113.64 |
| Basic Average Shares | 85.32 | 99.68 | 102.36 | 113.64 |
| Diluted NI Availto Com Stockholders | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Including Noncontrolling Interests | -22.33 | -50.62 | -62.03 | -64.78 |
| Net Income Continuous Operations | -22.33 | -50.62 | -62.03 | -64.78 |
| Other Income Expense | 0 | 0 | -0.01 | 0.01 |
| Other Non Operating Income Expenses | 0 | 0 | -0.01 | 0.01 |
| Net Non Operating Interest Income Expense | 0.59 | 5.05 | 3.11 | 2.66 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.59 | 5.05 | 3.11 | 2.66 |
| Other Operating Expenses | -0.59 | 0.19 | -2.37 | -2.55 |
| Depreciation Amortization Depletion Income Statement | 13.05 | 13.55 | 17.41 | 12.91 |
| Depreciation And Amortization In Income Statement | 13.05 | 13.55 | 17.41 | 12.91 |
| Amortization | 13.05 | 13.55 | 17.41 | 12.91 |
| Amortization Of Intangibles Income Statement | 13.05 | 13.55 | 17.41 | 12.91 |
| General And Administrative Expense | 24.90 | 33.31 | 30.74 | 29.21 |
| Other Gand A | 24.90 | 33.31 | 30.74 | 29.21 |
| Operating Revenue | 59.08 | 34.16 | 26.39 | 18.67 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OmniAb, Inc.this co. | OABI | $197M | - | 0.74 | -24.3% | -3.48 |
| OraSure Technologies, Inc. | OSUR | $205M | - | 0.61 | -20.2% | -0.32 |
| Atrium Therapeutics, Inc. | RNA | $202M | - | -3.21 | -37.0% | - |
| Replimune Group, Inc. | REPL | $197M | - | 0.90 | -59.5% | -0.01 |
| Lucid Diagnostics Inc. | LUCD | $194M | - | -3.11 |
| -530.4% |
| -4.51 |
| Nkarta, Inc. | NKTX | $192M | - | 0.61 | -33.3% | 0.08 |
| Inogen, Inc. | INGN | $191M | - | 0.99 | -11.8% | -9.27 |
| Cartesian Therapeutics, Inc. | RNAC | $190M | - | -1.33 | 103.2% | -0.70 |
| Quantum-Si incorporated | QSI | $187M | - | 0.85 | -46.0% | -0.31 |
| Peer Median | - | - | 0.61 | -35.2% | -0.32 | |